Estrogens and development of pulmonary hypertension: Lnteraction of estradiol metabolism and pulmonary vascular disease

Journal of Cardiovascular Pharmacology

Volumn 56, Issue 6, 2010, Pages 696-708

  Tofovic, Stevan P ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

2 methoxyestradiol; 2 methoxyestrone; Endothelial cells; Estradiol; Estradiol metabolism; Pulmonary arterial hypertension

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 HYDROXYESTRADIOL; 2 METHOXYESTRADIOL; 2 METHOXYESTRONE; ANDROGEN; ANDROSTENEDIONE; CATECHOL METHYLTRANSFERASE; ESTRADIOL; ESTROGEN; GESTAGEN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P27; RETINOIC ACID; TESTOSTERONE 17BETA DEHYDROGENASE; TUMOR NECROSIS FACTOR ALPHA;

DISEASE COURSE; DRUG METABOLISM; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; METABOLITE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; REVIEW; SMOOTH MUSCLE FIBER;

ANIMALS; ESTRADIOL; ESTROGENS; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES; VASCULAR DISEASES; VASCULAR RESISTANCE;

EID: 78751644250     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181f9ea8d     Document Type: Review

References (155)

1. Badesh BD, Champion HC, Gomez-Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54:S55-S56.
2. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54: S43-S54.
3. Voelkel NF, Quaife RA, Leinwand LA, et al. Right ventricular function and failure: report of a National Heart, Lung and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation. 2006;114:1883-1891.
4. Cool CD, Stewart JS, Werahera P, et al. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Am J Pathol. 1999;155:411-419.
5. Thenappan T, Shah SJ, Rich S, et al. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J. 2007;30: 1103-1110.
6. Jing ZC, Xu XQ, Han ZY, et al. Registry and survival study in Chinese patients with idiopathic and familial pulmonary hypertension. Chest. 2007;132:373-379.
7. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173:1023-1030.
8. Mendelson ME. Genomic and nongenomic effects of estrogen in the vasculature. Am J Cardiol. 2002;90:F3-F6.
9. Ling S, Komesaroff P, Sudhir K. Cellular mechanism underlying the cardiovascular actions of oestrogens. Clin Sci (Lond). 2006;111: 107-118.
10. Lantin-Hermoso RL, Rosenfeld CR, Yuhanna IS, et al. Estrogen acutely stimulates nitric oxide synthase activity in fetal pulmonary artery endothelium. Am J Physiol. 1997;273:L119-L126.
11. Sherman TS, Chambliss KL, Gibson LL, et al. Estrogen acutely activates prostacyclin synthesis in bovine fetal pulmonary artery endothelium. Am J Respir Cell Mol Biol. 2002;26:610-616.
12. MacRitchie AN, Jun SS, Chen Z, et al. Estrogen upregulates endothelial nitric oxide synthase gene expression in fetal pulmonary artery endothelium. Circ Res. 1997;81:355-362. (Pubitemid 27362522)
13. Earley S, Resta TC. Estradiol attenuates hypoxia-induced pulmonary endothelin-1 gene expression. Am J Physiol Lung Cell Mol Physiol. 2002;283:L86-L93. (Pubitemid 34764544)
14. English KM, Jones RD, Jones TH, et al. Gender differences in the vasomotor effects of different steroid hormones in rat pulmonary and coronary arteries. Horm Metab Res. 2001;33:645-652.
15. Gordon JB, Wetzel RC, McGeady ML, et al. Effects of indomethacin on estradiol-induced attenuation of hypoxic vasoconstriction in lamb lungs. J Appl Physiol. 1986;61:2116-2121.
16. Lahm T, Crisostomo PR, Markel TA, et al. The effects of estrogen on pulmonary artery vasoreactivity and hypoxic pulmonary vasoconstriction: potential new clinical implications for an old hormone. Crit Care Med. 2008;36:2174-2183.
17. Smith, PH, Moosavi M,Wilson M, et al. The influence of age and sex on the response of right ventricle, pulmonary vasculature, and carotid bodies to hypoxia in rats. J Pathol. 1974;112:11-18.
18. Rabinovitch M, Gamble WJ, Miettinen OS, et al. Age and sex influence on pulmonary hypertension of chronic hypoxia and recovery. Am J Physiol Heart Circ Physiol. 1981;240:H62-H72.
19. Resta TC, Knaggy NL, Walker BR. Estradiol-induced attenuation of pulmonary hypertension is not associated with altered eNOS expression. Am J Physiol Lung Cell Mol Physiol. 2001;280:L88-L97.
20. Stupfel M, Pesce VH, Gourlet V, et al. Sex-related factors in acute hypoxia survival in one strain of mice. Aviat Space Environ Med. 1984; 55:136-140.
21. Parker TA, Ivy DD, Galan HL, et al. Estradiol improves pulmonary hemodynamics and vascular remodeling in perinatal pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2000;278:L374-L381.
22. Kiyatake K, Kaneko N, Okada O, et al. Role of liver microsome for sexual difference in monocrotaline-treated rats. Am Rev Respir Dis. 1992;145:A650.
23. Kiyatake K, Kakusaka I, Kasahara Y, et al. Relationship between the converting ability of liver microsomes and monocrotaline-induced pulmonary hypertension in male, female and castrated male rats. Nihon Kyobu Shikkan Gakkai Zasshi. 1994;32:125-129.
24. Farhat MY, Chen MF, Bhatti T, et al. Protection by oestradiol against the development of cardiovascular changes associated with monocrotaline pulmonary hypertension in rats. Br J Pharmacol. 1993;110: 719-723.
25. Ahn BH, Park HK, Cho HG, et al. Estrogen and enalapril attenuate the development of right ventricular hypertrophy induced by monocrotaline in ovariectomized rats. J Korean Med Sci. 2003;18:641-648.
26. Nishida M, Hasegawa Y, Tanida I, et al. Preventive effects of raloxifene, a selective estrogen receptor modulator, on monocrotaline-induced pulmonary hypertension in intact and ovariectomized female rats. Eur J Pharmacol. 2009;614:70-76.
27. Homma N, Morio Y, Takahashi H, et al. Genistein, a phytoestrogen, attenuates monocrotaline-induced pulmonary hypertension. Respiration. 2006;73:105-112.
28. Meyrick B, Gamble W, Reid L. Development of Crotalaria pulmonary hypertension: hemodynamic and structural study. Am J Physiol Heart Circ Physiol. 1980;239:H692-H702.
29. Rosenberg H, Rabinovitch M. Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. Am J Physiol. 1988;255: H1484-H1491.
30. Stenmark KR, Meyrick B, Galie N, et al. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol. 2009;297:L1013-L1032.
31. Meyrick BO, Perkett EA. The sequence of cellular and hemodynamic changes of chronic pulmonary hypertension induced by hypoxia and other stimuli. Am Rev Respir Dis. 1989;140:1486-1489.
32. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res. 2006;99:675-691.
33. Bull TM, Coldren CD, Geraci MW, et al. Gene expression profiling in pulmonary hypertension. Proc Am Thorac Soc. 2007;4:117-120.
34. Taraseviciene-Stewart L, Kasahara Y, Alger L, et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell deathdependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 2001;15:427-438.
35. Taraseviciene-Stewart L, Gera L, Hirth P, et al. Bradykinin antagonist and a caspase inhibitor prevent severe pulmonary hypertension in a rat model. Can J Physiol Pharmacol. 2002;80:269-274.
36. Abe K, Toba M, Alzoubi A, et al. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation. 2010; 121:2747-2754.
37. Okada K, Tanaka Y, Bernstein M, et al. Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension. Am J Pathol. 1997;151:1019-1025.
38. Nishimura T, Faul JL, Berry GJ, et al. 40-O-(2-Hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med. 2001;163:498-502.
39. White RJ, Meoli DF, Swarthout RF, et al. Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2007;293: L583-L590.
40. Said SI, Hamidi SA, Dickman KG, et al. Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation. 2007;15:1260-1268.
41. Steiner MK, Syrkina OL, Kolliputi N, et al. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res. 2009;104:236-244.
42. Greenway S, van Suylen RJ, Du Marchie Sarvaas G, et al. S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy. Am J Pathol. 2004;164:253-262.
43. Merklinger SL, Wagner RA, Spiekerkoetter E, et al. Increased fibulin-5 and elastin in S100A4/Mts1 mice with pulmonary hypertension. Circ Res. 2005;97:596-604.
44. Song Y, Jones JE, Beppu H, et al. Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. Circulation. 2005; 112:553-562.
45. Ivy DD, McMurtry IF, Colvin K, et al. Development of occlusive neointimal lesions in distal pulmonary arteries of endothelin B receptordeficient rats: a new model of severe pulmonary arterial hypertension. Circulation. 2005;111:2988-2996.
46. Tofovic SP, Rafikova O.Preventive and therapeutic effects of 2- methoxyestradiol, but not estradiol, in severe occlusive pulmonary arterial hypertension in female rats. Am J Respir Crit Care Med. 2009; 179:A1802.
47. Dempsie Y, MacRitchie NA, Morecroft I, et al. The effects of gender on the development of dexfenfluramine-induced pulmonary hypertension in mice. Am J Respir Crit Care Med. 2009;179:A1808.
48. Dempsie Y, Nilsen M, Loughlin L, et al. The effects of gender on the development of pulmonary arterial hypertension in mice over-expressing the serotonin transporter. Am J Respir Crit Care Med. 2009;179:A1809.
49. Wood P. Pulmonary hypertension. Br Med Bull. 1952;8:348-353.
50. Rubin L. Primary pulmonary hypertension. N Engl J Med. 1997;33: 111-117.
51. Turini P, Allemann Y, Sartori C, et al. Protective effects of female sex hormones against pulmonary hypertension in Bolivian high altitude natives. Circulation. 2003;111:B54.
52. Scorza R, Caronni M, Bazzi S, et al. Post-menopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis. Ann N Y Acad Sci. 2002;966:238-246.
53. Arlett CM, Rasheed M, Russo-Stieglitz KE, et al. Influence of prior pregnancies on disease course and cause of death in systemic sclerosis. Ann Rheum Dis. 2002;61:346-350.
54. Austin ED, Cogan JD, West JD, et al. Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females. Eur Respir J. 2009;34:1093-1099.
55. Kawut S, Krowka MJ, Trotter JF, et al. Clinical risk factors for portopulmonary hypertension. Hepatology. 2008;48:196-203.
56. Roberts KE, Fallon MB, Krowka MJ, et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med. 2009;179:835-842.
57. Sweeney LB, Voelkel NF. Estrogen exposure in women with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2009;179:A4870.
58. Harda N, Sasano H, Mukamari H, et al. Localized expression of aromatase in human vascular tissues. Circ Res. 1999;84:1285-1291.
59. Park BK. Cytochrome P450 enzymes in the heart. Lancet. 2000;355: 945-946.
60. Lee AJ, Cai MX, Thomas PE, et al. Characterization of the oxidative metabolites of 17b estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003;144: 3382-3398.
61. Fishman J, Martucci C. Biological properties of 16a-hydroxyestrone: implications in estrogen physiology and pathophysiology. J Clin Endocrinol Metab. 1980;51:611-615.
62. Swanek GE, Fishman J. Covalent binding of the endogenous estrogen 16α-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci U S A. 1988;85:7831-7835.
63. Jellinck PH, Hahn EF, Fishman J. Absence of reactive intermediates in the formation of catechol estrogens by liver microsomes. J Biol Chem. 1986;261:7729-7732.
64. Jellinck PH, Fishman J. P-450-catalyzed oxidations. Biochemistry. 1988; 27:6111-6116.
65. Ball P, Emons G, Kayser H, et al. Metabolic clearance rates of catechol estrogens in rats. Endocrinology. 1983;113:1781-1783. (Pubitemid 13023820)
66. Liu D, Bachmann KA. An investigation of the relationship between estrogen, estrogen metabolites and blood cholesterol levels in ovariectomized rats. J Pharmacol Exp Ther. 1988;286:561-568.
67. Lakham NJ, Sarkar MA, Venitz J, et al. 2-Methoxyestradiol, a promising anticancer drug. Pharmacotherapy. 2003;23:165-172.
68. Farin FM, Pohlman TH, Omiecinski CJ. Expression of cytochrome P450s and microsomal epoxide hydrolase in primary cultures of human umbilical vein endothelial cells. Toxicol Appl Pharmacol. 1994;124:1-9.
69. Zacharia LC, Jackson EK, Gillespie DG, et al. Increased 2-Methoxyestradiol production in human coronary versus aortic vascular cells. Hypertension. 2001;37:658-662.
70. Dubey RK, Gillespie DG, Zacharia LC, et al. 2-Methoxyestradiol mediates the antimitogenic effects of locally applied estradiol on cardiac fibroblast growth. Hypertension. 2002;39:412-417.
71. Newman S, Ireson CR, Tutill HJ, et al. The role of 17b-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cells. Cancer Res. 2006;66:324-330.
72. Bayard F, Clamens S, Meggetto F, et al. Estrogen synthesis, estrogen metabolism, and functional estrogen receptors in rat arterial smooth muscle cells in culture. Endocrinology. 1995;136:1523-1529.
73. Piao Y-S, Peltoketo H, Jouppila A, et al. Retinoic acids increase 17ß-hydroxysteroid dehydrogenase type 1 expression in JEG-3 and T47D cells, but the stimulation is potentiated by epidermal growth factor, 12-O-tetradecanoylphorbol-13-acetate, and cyclic adenosine 3',5'- monophosphate only in JEG-3 cells. Endocrinology. 1997;138:898-904.
74. Tofovic SP, Zhu H, Jackson EK, et al. 2-Methoxyestrone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension. Eur Respir J. 2008;32(Suppl 52):S164.
75. Tofovic SP, Eman S, Mady H, et al. Estradiol metabolites attenuates monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol. 2005;46:430-437.
76. Tofovic SP, Jones TJ, Petrusevska G. Dose-dependent therapeutic effects of 2-methoxyestradiol on monocrotaline-induced pulmonary hypertension and vascular remodeling. Prilozi (Contributions). 2010;31.279-295.
77. Tofovic SP, Zhang X, Jackson EK, et al. 2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension. Vasc Pharmacol. 2006;45:358-367.
78. Tofovic SP, Zhang X, Zhu H, et al. 2-Ethoxyestradiol is antimitogenic and attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling. Vasc Pharmacol. 2008;48:174-183.
79. Tofovic SP, Jackson EK, Rafikova O. Synergistic effects of 2- methoxyestradiol and retinoic acid on amelioration of monocrotalineinduced pulmonary hypertension. Am J Respir Crit Care Med. 2008;177: A592.
80. Tofovic SP, Jones TJ, Bilan V, et al. Synergistic effects of 2- methoxyestradiol with either sildenafil or bosentan on amelioration of monocrotaline-induced pulmonary hypertension and vascular remodeling. J Cardiovasc Pharmacol. 2010. In press.
81. Tofovic SP, Zhang X, Jones T, et al. 2-Methoxyestradiol attenuates the development and retards the progression of chronic hypoxia-induced pulmonary hypertension in rats. Circulation. 2005;112:98-99.
82. Hampl V, Bíbová J, Povysilová V, et al. Dehydroepiandrosterone sulfate reduces chronic hypoxic pulmonary hypertension in rats. Eur Respir J. 2003;21:862-865. (Pubitemid 36592298)
83. Oka M, Karoor V, Homma N, et al. Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension. Cardiovasc Res. 2007;74:377-387.
84. Tofovic SP, Zhang X, Jackson EK, et al. 2-Methoxyestradiol attenuates bleomycin-induced pulmonary hypertension and fibrosis in estrogendeficient rats. Vasc Pharmacol. 2009;51:190-197.
85. Tofovic SP, Jackson EK, Zhang X. 2-Methoxyestradiol attenuates pulmonary hypertension induced by a-naphthylthiourea. FASEB J. 2005; 19:A1333.
86. Tofovic SP, Zhang X, Petrusevska G. Progesterone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension in estrogen deficient rats. Prilozi (Contributions). 2009;30:5-24.
87. Jones TJ, Zhang X, Jackson EK, et al. Medroxyprogesterone acetate attenuates and tibolone prevents the development of monocrotalineinduced pulmonary hypertension. FASEB J. 2006;20:A402.
88. Homma N, Nagaoka T, Karoor V, et al. Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone. Am J Physiol Lung Cell Mol Physiol. 2008;295:L71-L78.
89. Alzoubi A, Toba M, Abe K, et al. Dehydroepiandrosterone attenuates established severe pulmonary arterial hypertension in rats. Am J Respir Crit Care Med. 2010;181:A6302.
90. Sweeney LB, Bogaard HJ, Natarajan R, et al. Female gender protects against angioproliferative pulmonary hypertension induced by VEGF receptor inhibition and hypoxic exposure. Am J Respir Crit Care Med. 2009;179:A1826.
91. Tofovic SP, Jackson EK, Tofoski GJ. Dysregulated estradiol metabolism in preeclampsia. Physiologist. 2007;50:21.
92. Thorneycroft IH, Mishell DR Jr, Stone SC, et al. The relation of serum 17-hydroxyprogesterone and estradiol-17-beta levels during the human menstrual cycle. Am J Obstet Gynecol. 1971;111:947-951.
93. Hoshikawa Y, Ono S, Suzuki S, et al. Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J Appl Physiol. 2001;90:1299-1306.
94. Fradette C, Batonga J, Teng S, et al. Animal models of acute moderate hypoxia are associated with a down-regulation of CYP1A1, 1A2, 2B4, 2C5, and 2C16 and up-regulation of CYP3A6 and P-glycoprotein in liver. Drug Metab Dispos. 2007;35:765-771.
95. Taherzadeh M, Fradette C, Bleau A-M, et al. The 21-aminosteroid U74389G prevents the down-regulation and decrease in activity of CYP1A1, 1A2 and 3A6 induced by an inflammatory reaction. Biochem Pharmacol. 2006;71:366-376.
96. Pak O, Aldashev A,Welsh D, et al. The effects of hypoxia on the cells of the pulmonary vasculature. Eur Respir J. 2007;30:364-372.
97. Kleinman ME, Greives MR, Churgin SS, et al. Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma. Arterioscler Thromb Vasc Biol. 2007;27:2664-2670.
98. Tuder RM, Voelkel NF. Pulmonary hypertension and inflammation. J Lab Clin Med. 1998;132:16-24.
99. Hassoun PM, Mouthon L, Barberà JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol. 2009; 54(Suppl 1):S10-S19.
100. Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med. 1995;151:1628-1631.
101. Nicolls MR, Taraseviciene-Stewart L, Rai PR, et al. Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J. 2005;26:1110-1118.
102. Folomeev M, Dougados M, Beanue J, et al. Plasma sex hormones and aromatase activity in tissues of patients with systemic lupus erythematous. Lupus. 1992;1:191-195.
103. Reed MJ, Coldham NG, Patel SR, et al. Interleukin-1 and interleukin-6 in breast cyst fluid: their role in regulating aromatase activity in breast cancer cells. J Endocrinol. 1992;132:R5-R8.
104. Macdiarmid F, Wang D, Duncan LJ, et al. Stimulation of aromatase activity in breast fibroblasts by tumor necrosis factor. Mol Cell Endocrinol. 1994;106:17-21.
105. Seriolo B, Accardo S, Garnero A, et al. Association between anticardiolipin antibody positivity and increased 17-beta-estradiol levels in premenopausal women with rheumatoid arthritis. Ann N Y Acad Sci. 1999;876:159-163.
106. Zuckerman SH, Ahmari SE, Bryan-Poole N, et al. Estriol: a potent regulator of TNF and IL-6 expression in a murine model of endotoxemia. Inflammation. 1996;20:581-597.
107. Purohit A, Singh A, Ghlchik MW, et al. Inhibition of tumor necrosis factor a-stimulated aromatase activity by microtubule-stabilizing agents, paclitaxel and 2-methoxyestradiol. Biochem Biophys Res Commun. 1999;261:214-217.
108. Castagnetta LA, Carruba G, Granata OM, et al. Increased estrogen formation and estrogen to androgen ratio in the synovial fluid of patients with rheumatoid arthritis. J Rheumatol. 2003;30:2597-2605.
109. Cutolo M, Capellino S, Sulli A, et al. Estrogens and autoimmune diseases. Ann N Y Acad Sci. 2006;1089:538-547.
110. Tuder RM, Voelkel NF. Angiogenesis and pulmonary hypertension. A unique process in a unique disease. Antioxid Redox Signal. 2002;4: 833-843.
111. Tuder RM, Cool CD, GeracuMW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999;159:1925-1932.
112. Glaid A, Salah D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333:214-221.
113. Glaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732-1739.
114. Tuder RM, Chacon M, Alger L, et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol. 2001;195:367-374.
115. Loscalzo J. Endothelial dysfunction in pulmonary hypertension. N Engl J Med. 1992;327:70-75.
116. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system N Engl J Med. 1999;340:1801-1811.
117. Klouche M. Estrogens in human vascular diseases. Ann N Y Acad Sci. 2006;1089:431-443.
118. Farhat MY, Vargas R, Dingaan B, et al. In vitro effect of oestradiol on thymidine uptake in pulmonary vascular smooth muscle cell: role of the endothelium. Br J Pharmacol. 1992;107:679-683.
119. Lippert C, Seeger H, Mueck AO, et al. The effects of A-ring and D-ring metabolites of estradiol on the proliferation of vascular endothelial cells. Life Sci. 2000;67:1653-1658.
120. Dupont J, Karas M, LeRoith D. The potentiation of estrogen of insulinlike growth factor I action in MCF-7 human cancer cells includes cell cycle components. J Biol Chem. 2000;275:35893-35900.
121. Suzuma, I, Mandai M, Takagi H, et al. 17-Estradiol increases VEGF receptor-2 and promotes DNA synthesis in retinal microvascular endothelial cells. Invest Ophthalmol Vis Sci. 1999;40:2122-2129.
122. Geraldes P, Sirois MG, Bernatchez PN, et al. Estrogen regulation of endothelial and smooth muscle cell migration and proliferation. Role of p38 and p42/44 mitogen-activate protein kinase. Arterioscler Thromb Vasc Biol. 2002;22:1585-1590.
123. Spyridopoulos I, Sullivan AB, Kearney M, et al. Estrogen-receptormediated inhibition of human endothelial cell apoptosis. Estradiol as a survival factor. Circulation. 1997;95:1505-1514.
124. Lai Y-L, Law TC. Chronic hypoxia and monocrotaline-induced elevation of hypoxia-inducible factor-1a levels and pulmonary hypertension. J Biomed Sci. 2004;11:315-321.
125. Shang W, Konidari I, Schomberg DW. 2-Methoxyestradiol, an endogenous estradiol metabolite, differentially inhibits granulosa and endothelial cell mitosis: a potential follicular antiangiogenic regulator. Biol Reprod. 2001;65:622-627.
126. Dubey RK, Tofovic SP, Jackson EK. Cardiovascular pharmacology of estradiol metabolites. J Pharmcol Exp Ther. 2004;308:403-409.
127. Tomaszewski J, Adamiak A, Skorupski P, et al. Effects of 17 betaestradiol and phytoestrogen daidzein on the proliferation of pubocervical fascia and skin fibroblast derived from women suffering from stress urinary incontinence. Ginekol Pol. 2003;74:1410-1414.
128. Kondo H, Kasuga H, Noumura T. Effects of various steroids on in vitro lifespan and cell growth of human fetal lung fibroblasts (WI-38). Mech Ageing Dev. 1983;21:335-344.
129. Kamath K, Okouneva T, Larson G, et al. 2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules. Mol Cancer Ther. 2006;5:2225-2233.
130. Seeger H, Mueck AO, Lippert TH. Effects of estradiol metabolites on prostacyclin synthesis in human endothelial cell cultures. Life Sci. 1999; 65:167-170.
131. Tsukamoto A, Kaneko Y, Yoshida T, et al. 2-Methoxyestradiol, an endogenous metabolite of estrogen, enhances apoptosis and betagalactosidase expression in vascular endothelial cells. Biochem Biophys Res Commun. 1998;248:9-12.
132. Dubey RK, Jackson EK, Keller PJ, et al. Estradiol metabolites inhibit endothelin synthesis by an estrogen receptor-independent mechanism. Hypertension. 2001;37:640-644.
133. Fenoy FJ, Hernandez ME, Hernandez M, et al. Acute effects of 2- methoxyestradiol on endothelial aortic NO release in male and ovariectomized female rats. Nitric Oxide. 2010;23:12-19.
134. Fotsis T, Zhang Y, Pepper MS, et al. The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumor growth. Nature. 1994;17:237-239.
135. Yue TL, Wang X, Louden CS, et al. 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression. Mol Pharmacol. 1997;51:951-962.
136. Barchiesi F, Jackson EK, Fingerle J, et al. 2-Methoxyestradiol, an estradiol metabolite, inhibits neointima formation and smooth muscle cell growth via double blockade of the cell cycle. Circ Res. 2006;99:266-274.
137. Ricker JL, Chen Z, Yang XP, et al. 2-Methoxyestradiol inhibits hypoxiainducible factor 1alpha, tumor growth and angiogenesis and augments paclitaxel efficacy in heart and neck squamous cell carcinoma. Clin Cancer Res. 2004;10:8665-8673.
138. Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell. 2003;3:363-375.
139. Semenza GL. HIF-1 and human disease: one highly involved factor. Genes Dev. 2000;14:1983-1991.
140. Yu AY, Shimoda LA, Iyer NV, et al. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1 alpha. J Clin Invest. 1999;103:691-696.
141. Brusselmans K, Compernolle V, Tjwa M, et al. Heterozygous deficiency of hypoxia-inducible factor-2a protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J Clin Invest. 2003;111:1519-1527.
142. Salama SA, Kamel MW, Botting S, et al. Catechol-O-methyltransferase expression and 2-methoxyestradiol affect microtubule dynamics and modify steroid receptor signaling in leiomyoma cells. PLoS One. 2009;4:e7356.
143. Vijayanathan V, Venkiteswaran S, Nair SK, et al. Physiologic levels of 2-methoxyestradiol interfere with nongenomic signaling of 17b-estradiol in human breast cancer cells. Clin Cancer Res. 2006;12:2038-2048.
144. Welter BH, Hansen EL, Saner KJ, et al. Membrane-bound progesterone receptor expression in human aortic endothelial cells. J Histochem Cytochem. 2003;51:1049-1055.
145. Barberis MC, Veronese S, Bauer D, et al. Immunocytochemical detection of progesterone receptors. A study in a patient with primary pulmonary hypertension. Chest. 1995;107:869-872.
146. Vazquez F, Rodriguez-Menzaneque JC, Lydon JP, et al. Progesterone regulates proliferation of endothelial cells. Biol Chem. 1999;274: 2185-2192.
147. Morey AK, Pedram A, Razandi M, et al. Estrogen and progesterone inhibit vascular smooth muscle proliferation. Endocrinology. 1997;138: 3300-3339.
148. Lee WS, Harder JA, Yoshizumi M, et al. Progesterone inhibits arterial smooth muscle cell proliferation. Nat Med. 1997;3:1005-1008.
149. Lee W-S, Liu C-W, Juan S-H, et al. Molecular mechanism of progesterone-induced antiproliferation in rat aortic smooth muscle cells. Endocrinology. 2003;144:2785-2790.
150. Li H-F, Zhen T-Z, Li W, et al. Effects of progesterone on the contractile response of isolated pulmonary artery in rabbits. Can J Physiol Pharmacol. 2001;79:545-550.
151. Jones RD, English KM, Pugh PJ, et al. Pulmonary vasodilatory action of testosterone: evidence of a calcium antagonistic action. J Cardiovasc Pharmacol. 2002;39:814-823.
152. Smith AM, Bennett RT, Jones HT, et al. Characterization of the vasodilatory action of testosterone in the human pulmonary circulation. Vasc Health Risk Manag. 2008;4:1459-1466.
153. Bonnet S, Dumas-de-La-Roque E, Bégueret H, et al. Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension. Proc Natl Acad Sci U S A. 2003;100:9488-9493.
154. Mueck AO, Seeger H. 2-Methoxyestradiol-biology and mechanism of action. Steroids. 2010;75:625-631.
155. Tofovic SP, Jackson EK, Piche C. Pharmacokinetics and safety of a subcutaneously injected long-acting formulation of 2-methoxyestradiol (2ME) in healthy volunteers. Basic Clin Pharmacol Toxicol. 2009; 105(Suppl 1):107.